|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.95 USD | +5.58% |
|
+10.82% | +66.30% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Evolution of the Average Target: Intellia Therapeutics, Inc.
Evolution of the Target Price: Intellia Therapeutics, Inc.
Changes in Analyst Recommendations: Intellia Therapeutics, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +69.14% | |||||
| +23.96% | |||||
| +26.04% | |||||
| +7.33% | |||||
| +24.06% | |||||
| +31.25% | |||||
| +21.31% | |||||
| -3.94% | |||||
| +2.88% | |||||
| Average | +22.45% | |||||
| Weighted average by Cap. | +19.86% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Chardan Research | |
| RBC Capital Markets | |
| William Blair & Co. | |
| Wedbush | |
| BofA Securities | |
| JonesTrading Institutional Services | |
| Evercore ISI | |
| Truist Securities | |
| JPMorgan Chase | |
| Wells Fargo Securities | |
| Wolfe Research | |
| HC Wainwright | |
| Morgan Stanley | |
| Canaccord Genuity | |
| Oppenheimer | |
| Goldman Sachs | |
| Barclays | |
| Citigroup | |
| BMO Capital | |
| Raymond James | |
| Bernstein | |
| Credit Suisse | |
| EF Hutton | |
| Baird | |
| Cantor Fitzgerald | |
| SVB Securities LLC | |
| JMP Securities | |
| Piper Sandler | |
| Guggenheim | |
| Brookline Capital Markets | |
| Cowen | |
| Stifel Nicolaus | |
| Chardan | |
| Roth Capital Partners | |
| Jefferies & Co. |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NTLA Stock
- Consensus Intellia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
